These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 28499900

  • 1. Lurasidone in post-menopausal females with major depressive disorder with mixed features: Post-hoc analysis of a placebo-controlled trial.
    Sramek J, Loebel A, Murphy M, Mao Y, Pikalov A, Cutler NR.
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug 01; 78():12-17. PubMed ID: 28499900
    [Abstract] [Full Text] [Related]

  • 2. Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study.
    Tsai J, Thase ME, Mao Y, Ng-Mak D, Pikalov A, Loebel A.
    CNS Spectr; 2017 Apr 01; 22(2):236-245. PubMed ID: 28357969
    [Abstract] [Full Text] [Related]

  • 3. Remission and recovery associated with lurasidone in the treatment of major depressive disorder with subthreshold hypomanic symptoms (mixed features): post-hoc analysis of a randomized, placebo-controlled study with longer-term extension.
    Goldberg JF, Ng-Mak D, Siu C, Chuang CC, Rajagopalan K, Loebel A.
    CNS Spectr; 2017 Apr 01; 22(2):220-227. PubMed ID: 28264739
    [Abstract] [Full Text] [Related]

  • 4. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study.
    Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, Pikalov A, Loebel A.
    Am J Psychiatry; 2016 Apr 01; 173(4):400-7. PubMed ID: 26552942
    [Abstract] [Full Text] [Related]

  • 5. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.
    Swann AC, Fava M, Tsai J, Mao Y, Pikalov A, Loebel A.
    CNS Spectr; 2017 Apr 01; 22(2):228-235. PubMed ID: 28300012
    [Abstract] [Full Text] [Related]

  • 6. Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features): Results From a Placebo-Controlled Trial.
    Clayton AH, Tsai J, Mao Y, Pikalov A, Loebel A.
    J Clin Psychiatry; 2018 Aug 07; 79(5):. PubMed ID: 30086213
    [Abstract] [Full Text] [Related]

  • 7. Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model.
    Goldberg JF, Siu C, Mao Y, Tsai J, Pikalov A, Calabrese JR, Loebel A.
    J Affect Disord; 2020 Dec 01; 277():1045-1054. PubMed ID: 33065813
    [Abstract] [Full Text] [Related]

  • 8. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial.
    McIntyre RS, Cucchiaro J, Pikalov A, Kroger H, Loebel A.
    J Clin Psychiatry; 2015 Apr 01; 76(4):398-405. PubMed ID: 25844756
    [Abstract] [Full Text] [Related]

  • 9. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial.
    Singh MK, Pikalov A, Siu C, Tocco M, Loebel A.
    J Child Adolesc Psychopharmacol; 2020 Dec 01; 30(10):590-598. PubMed ID: 32392455
    [Abstract] [Full Text] [Related]

  • 10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun 01; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 11. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
    Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD.
    CNS Spectr; 2015 Apr 01; 20(2):140-7. PubMed ID: 24955752
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.
    Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, Loebel A.
    J Clin Psychiatry; 2016 Oct 01; 77(10):e1324-e1331. PubMed ID: 27529375
    [Abstract] [Full Text] [Related]

  • 13. Major depressive disorder with subthreshold hypomania (mixed features): Clinical characteristics of patients entered in a multiregional, placebo-controlled study.
    Targum SD, Suppes T, Pendergrass JC, Lee S, Silva R, Cucchiaro J, Loebel A.
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jul 04; 68():9-14. PubMed ID: 26908089
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
    Goldman R, Loebel A, Cucchiaro J, Deng L, Findling RL.
    J Child Adolesc Psychopharmacol; 2017 Aug 04; 27(6):516-525. PubMed ID: 28475373
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study.
    DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A.
    J Am Acad Child Adolesc Psychiatry; 2017 Dec 04; 56(12):1015-1025. PubMed ID: 29173735
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG.
    Schizophr Res; 2013 Apr 04; 145(1-3):101-9. PubMed ID: 23415311
    [Abstract] [Full Text] [Related]

  • 17. Lurasidone Efficacy in Mixed Depressive States: A Comparison of Standard Rating Scales to the Koukopoulos Mixed Depression Rating Scale.
    Vöhringer PA, Sani G, Barroilhet SA, Mao Y, Ghaemi SN.
    J Clin Psychopharmacol; 2020 Apr 04; 40(5):491-494. PubMed ID: 32701901
    [Abstract] [Full Text] [Related]

  • 18. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
    Suppes T, Kroger H, Pikalov A, Loebel A.
    J Psychiatr Res; 2016 Jul 04; 78():86-93. PubMed ID: 27089521
    [Abstract] [Full Text] [Related]

  • 19. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
    Kornstein SG, Jiang Q, Reddy S, Musgnung JJ, Guico-Pabia CJ.
    J Clin Psychiatry; 2010 Aug 04; 71(8):1088-96. PubMed ID: 20797382
    [Abstract] [Full Text] [Related]

  • 20. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
    Rajagopalan K, Bacci ED, Ng-Mak D, Wyrwich K, Pikalov A, Loebel A.
    BMC Psychiatry; 2016 May 23; 16():157. PubMed ID: 27215976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.